New drug combo for first-line head and neck cancer
Part of Cancer clinical trials.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer that has spread or come back and can't be cured with local treatments like surgery or radiation.
- You have not had any chemotherapy or targeted therapy for this current episode of cancer (or if you did, it finished more than 6 months ago).
- Your tumor has certain proteins (PD-L1 and TROP2) that can be detected from a biopsy sample.
- You are generally in good health, able to take care of yourself (ECOG 0 or 1), and your blood, liver, kidneys are working well.
- You are willing to use birth control during and for 12 months after treatment if you could become pregnant or get someone pregnant.
- You do not have active infections like hepatitis B or C, HIV, or an autoimmune disease that needs strong medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This study tests whether giving a combination of two medications before surgery can help shrink oral cancer tumors and improve treatment outcomes. The medications are a targeted therapy (called TROP-2 ADC) and an immunotherapy (called toripalimab), and you would receive them before your planned surgery.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new combination of two drugs—sacituzumab tirumotecan (a targeted therapy) plus an immunotherapy—for people whose head and neck cancer has returned or spread after standard treatment. The goal is to see if this combination can shrink tumors and delay cancer growth.
Hear when a new Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.